<DOC>
	<DOCNO>NCT00451217</DOCNO>
	<brief_summary>The purpose study demonstrate adult patient faster recovery neuromuscular block induce either rocuronium vecuronium reversal reappearance T2 2.0 mg/kg Org 25969 ( sugammadex ) compare 50 ug/kg neostigmine .</brief_summary>
	<brief_title>Comparison Org 25969 With Neostigmine Reversal Agents Rocuronium Vecuronium Reappearance T2 ( 19.4.301 ) ( P05960 )</brief_title>
	<detailed_description />
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Subjects ASA 1 4 ; Subjects equal age 18 ; Scheduled surgical procedure general anesthesia use rocuronium vecuronium endotracheal intubation maintenance neuromuscular block ; Scheduled surgical procedure supine position ; Given write informed consent . Subjects difficult intubation anatomical malformation expect ; Subjects know suspect neuromuscular disorder impair neuromuscular block ( NMB ) and/or significant renal dysfunction ; Subjects know suspect ( family ) history malignant hyperthermia ; Subjects know suspect allergy narcotic , muscle relaxant medication use general anesthesia ; Subjects receive medication dose and/or time point know interfere neuromuscular block agent antibiotic , anticonvulsant Mg2+ ; Subjects use neostigmine and/or glycopyrrolate may contraindicate ; Subjects already participate Org 25969 trial ; Subjects participate another clinical trial , preapproved NV Organon , within 30 day enter CT 19.4.301 . Female subject pregnant : Female subject childbearing potential use method birth control : condom use hormonal contraception birth control ; Female subject breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>